Enovis Corporation Common Stock (ENOV)
Stock · NYSE · Health Care
$19.61as of 10/16/2026
Price chart
Active signals
ENOV Signal Track Record
How signals performed across all stocks →What ENOV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -3.9% | 39% | September 1, 2026 |
| Bollinger Band Breakdown | 23 | -4.9% | 26% | September 1, 2026 |
| Bollinger Band BreakoutActive now | 22 | -5.1% | 36% | July 6, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -7.2% | 36% | August 24, 2026 |
| Any 20-session window (baseline) | -2.9% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electr…
- Sector
- Health Care
- Industry
- Industrial Specialties
- Employees
- 7,802
- Website
- www.enovis.com/
Fundamentals
- 1-day range
- $18.42$19.44
- Market cap
- $1.51B
- P/E (trailing)
- —
- P/E (forward)
- 5.46
- EPS (trailing)
- $-19.27
- Dividend yield
- —
- Beta
- 1.45
- Avg. volume
- 1.47M
How Enovis Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Enovis Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ENOVEnovis Corporation Common Stock$19.59▲ 1.24%Market cap $1.51BP/E —$16.7$34.28
- CDRECadre Holdings Inc. Common Stock$26.38▲ 1.77%Market cap $1.50BP/E 30.60$24.07$48.76
- WLFCWillis Lease Finance Corporation Common Stock$37.61▼ 2.18%Market cap $1.35BP/E 10.50$37.59$81.54
- XPELXPEL Inc. Common Stock$43.81▼ 1.11%Market cap $1.31BP/E 22.87$31.88$55.91
- ADSEADS-TEC ENERGY PLC Ordinary Shares$9.93▼ 0.70%Market cap $879.02MP/E —$9.05$13.5
- AVRAnteris Technologies Global Corp. Common Stock$6.05▼ 4.87%Market cap $813.78MP/E —$3.3$11.06
- ESTAEstablishment Labs Holdings Inc. Common Shares$59.18▼ 3.55%Market cap $2.33BP/E —$38.55$97.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENOV Enovis Corporation Common Stock | $1.51B | — | $19.59 | ▲ 1.24% | $16.7$34.28 |
| CDRE Cadre Holdings Inc. Common Stock | $1.50B | 30.60 | $26.38 | ▲ 1.77% | $24.07$48.76 |
| WLFC Willis Lease Finance Corporation Common Stock | $1.35B | 10.50 | $37.61 | ▼ 2.18% | $37.59$81.54 |
| XPEL XPEL Inc. Common Stock | $1.31B | 22.87 | $43.81 | ▼ 1.11% | $31.88$55.91 |
| ADSE ADS-TEC ENERGY PLC Ordinary Shares | $879.02M | — | $9.93 | ▼ 0.70% | $9.05$13.5 |
| AVR Anteris Technologies Global Corp. Common Stock | $813.78M | — | $6.05 | ▼ 4.87% | $3.3$11.06 |
| ESTA Establishment Labs Holdings Inc. Common Shares | $2.33B | — | $59.18 | ▼ 3.55% | $38.55$97.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Needham Maintains Buy on Enovis, Lowers Price Target to $34benzinga · 10/12/2026
- Enovis (ENOV), Why Is Fresh Attention Building Now?Yahoo · 10/10/2026
- Is Enovis (ENOV) Stock Cheap After Reaffirming 2026 Guidance?Yahoo · 10/10/2026
- 1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We AvoidYahoo · 10/8/2026
- Enovis to Host Third Quarter 2026 Results Conference Call on November 5thYahoo · 10/8/2026
- Transcript: Enovis Q2 2026 Earnings Conference CallBenzinga · 10/6/2026
- 3 Small-Cap Stocks We Approach with CautionYahoo · 10/5/2026
- 1 Oversold Stock Ready to Bounce Back and 2 That UnderwhelmYahoo · 9/28/2026
- Sports Rehabilitation Equipment Market Global Report 2026: Capitalize on a $2.05 Billion Revenue Surge to $6.84 Billion by 2030 as AI and Robotics Disrupt Recovery—Benchmark Stryker, Smith & Nephew, Enovis, Performance Health and Life FitnessYahoo · 9/28/2026
Insider Activity
Insider Actions →- Christine Ortiz · September 30, 2026 · Grant958
- Oliver Engert · September 4, 2026 · Buy2.7K @ $18.8
- Damien McDonald · September 4, 2026 · Buy13.0K @ $19.15
- Oliver Engert · September 3, 2026 · Buy5.1K @ $19.46
- Oliver Engert · September 2, 2026 · Buy2.5K @ $20.32
- Christine Ortiz · June 30, 2026 · Grant846
- Oliver Engert · June 15, 2026 · Buy1.0K @ $20.92
- Oliver Engert · June 11, 2026 · Grant1.0K @ $20.99
- Oliver Engert · June 11, 2026 · Buy1.0K @ $21.75
- Oliver Engert · June 11, 2026 · Buy200 @ $20.99
- Oliver Engert · June 10, 2026 · Buy1.0K @ $23
- Oliver Engert · June 1, 2026 · Buy1.0K @ $22.22
- Angela S. Lalor · May 19, 2026 · Grant9.3K
- A. Clayton Perfall · May 19, 2026 · Grant9.3K
- Brady Shirley · May 19, 2026 · Grant9.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 65.10M
- Total value held
- $1.45B
- Institutional holders
- 247
- Unknown9.94M
- Unknown4.77M
- Unknown2.55M
- Unknown2.55M
- Unknown2.45M
- Unknown2.44M
- Unknown2.40M
- Unknown2.40M
- Unknown1.78M
- Unknown1.76M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Enovis joins AAOS Registry Program as industry sponsor
Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.
Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.